Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT02352948




Registration number
NCT02352948
Ethics application status
Date submitted
28/01/2015
Date registered
2/02/2015
Date last updated
26/07/2024

Titles & IDs
Public title
A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Scientific title
A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC).
Secondary ID [1] 0 0
2014-000338-46
Secondary ID [2] 0 0
D4191C00004
Universal Trial Number (UTN)
Trial acronym
ARCTIC
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non - Small Cell Lung Cancer NSCLC 0 0
Condition category
Condition code
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MEDI4736 (durvalumab)
Treatment: Drugs - Vinorelbine
Treatment: Drugs - Gemcitabine
Treatment: Drugs - Erlotinib
Treatment: Drugs - MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)
Treatment: Drugs - tremelimumab (anti-CTLA4)

Experimental: MEDI4736 (durvalumab) monotherapy in Sub-study A - MEDI4736 (durvalumab) by intravenous infusion. Sub-study A for patients with PD-L1 positive tumors.

Active comparator: Standard of Care in Sub-study A - Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study A for patients with PD-L1 positive tumors.

Experimental: MEDI4736 (durvalumab) + tremelimumab in Sub-study B - MEDI4736 (durvalumab) by intravenous infusion and tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.

Active comparator: Standard of Care in Sub-study B - Investigator choice from Vinorelbine, Gemcitabine and Erlotinib. Sub-study B for patients with PD-L1 negative tumors.

Experimental: MEDI4736 (durvalumab) monotherapy in Sub-study B - MEDI4736 (durvalumab) by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.

Experimental: tremelimumab in Sub-study B - tremelimumab by intravenous infusion. Sub-study B for patients with PD-L1 negative tumors.


Treatment: Drugs: MEDI4736 (durvalumab)
MEDI4736 (durvalumab) treatment by intravenous infusion

Treatment: Drugs: Vinorelbine
Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.

Treatment: Drugs: Gemcitabine
Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.

Treatment: Drugs: Erlotinib
Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration

Treatment: Drugs: MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4)
MEDI4736 (durvalumab) in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion

Treatment: Drugs: tremelimumab (anti-CTLA4)
tremelimumab (anti-CTLA4) treatment by intravenous infusion
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Overall Survival (OS)
Timepoint [1] 0 0
From randomization (Day 1) until death due to any cause, approximately 36 months
Primary outcome [2] 0 0
Progression-Free Survival (PFS)
Timepoint [2] 0 0
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Secondary outcome [1] 0 0
OS, Contribution of the Components Analysis of Sub-study B
Timepoint [1] 0 0
From randomization (Day 1) until death due to any cause, approximately 36 months
Secondary outcome [2] 0 0
Percentage of Participants Alive at 12 Months (OS12)
Timepoint [2] 0 0
From randomization (Day 1) up to 12 months
Secondary outcome [3] 0 0
PFS, Contribution of the Components Analysis of Sub-study B
Timepoint [3] 0 0
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Secondary outcome [4] 0 0
Objective Response Rate (ORR)
Timepoint [4] 0 0
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Secondary outcome [5] 0 0
Duration of Response (DoR)
Timepoint [5] 0 0
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed up to a maximum of approximately 3 years.
Secondary outcome [6] 0 0
Percentage of Participants Alive and Progression Free at 6 Months (APF6)
Timepoint [6] 0 0
Tumour scans performed at baseline then every ~8 weeks up to 6 months
Secondary outcome [7] 0 0
Percentage of Participants Alive and Progression Free at 12 Months (APF12)
Timepoint [7] 0 0
Tumour scans performed at baseline then every ~8 weeks up to 12 months.
Secondary outcome [8] 0 0
Time From Randomisation to Second Progression (PFS2) of Sub-study B
Timepoint [8] 0 0
Tumour scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until first progression. Disease then assessed per local practice until 2nd progression. Assessed up to a maximum of approximately 3 years.

Eligibility
Key inclusion criteria
* Aged at least 18 years
* Documented evidence of NSCLC (Stage IIIB/ IV disease)
* Disease progression or recurrence after both a platinum-based chemotherapy regimen and at least 1 additional regimen for treatment of NSCLC
* World Health Organization (WHO) Performance Status of 0 or 1
* Estimated life expectancy more than 12 weeks
Minimum age
18 Years
Maximum age
130 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior exposure to any anti-PD-1 or anti-PD-L1 antibody or anti-CTLA4
* Brain metastases or spinal cord compression unless asymptomatic, treated and stable (not requiring steroids)
* Active or prior documented autoimmune disease within the past 2 years
* Evidence of severe or uncontrolled systemic disease, including active bleeding diatheses or active infections including hepatitis B, C and HIV
* Any unresolved toxicity CTCAE (Common Terminology Criteria of Adverse Events) >Grade 2 from previous anti-cancer therapy
* Known EGFR TK activating mutations or ALK rearrangements
* Any prior Grade =3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1
* Active or prior documented inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/01/2015
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/08/2023
Sample size
Target
Accrual to date
Final
597
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Research Site - Murdoch
Recruitment hospital [2] 0 0
Research Site - Port Macquarie
Recruitment postcode(s) [1] 0 0
6150 - Murdoch
Recruitment postcode(s) [2] 0 0
2444 - Port Macquarie
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Iowa
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
North Carolina
Country [15] 0 0
United States of America
State/province [15] 0 0
Ohio
Country [16] 0 0
United States of America
State/province [16] 0 0
Tennessee
Country [17] 0 0
United States of America
State/province [17] 0 0
Utah
Country [18] 0 0
United States of America
State/province [18] 0 0
Washington
Country [19] 0 0
Belgium
State/province [19] 0 0
Charleroi
Country [20] 0 0
Belgium
State/province [20] 0 0
Gent
Country [21] 0 0
Belgium
State/province [21] 0 0
Libramont-Chevigny
Country [22] 0 0
Belgium
State/province [22] 0 0
Mons
Country [23] 0 0
Belgium
State/province [23] 0 0
Roeselare
Country [24] 0 0
Belgium
State/province [24] 0 0
Yvoir
Country [25] 0 0
Bulgaria
State/province [25] 0 0
Pleven
Country [26] 0 0
Bulgaria
State/province [26] 0 0
Sofia
Country [27] 0 0
Bulgaria
State/province [27] 0 0
Varna
Country [28] 0 0
Canada
State/province [28] 0 0
New Brunswick
Country [29] 0 0
Chile
State/province [29] 0 0
Santiago
Country [30] 0 0
Chile
State/province [30] 0 0
Temuco
Country [31] 0 0
Czechia
State/province [31] 0 0
Nova Ves pod Plesi
Country [32] 0 0
Czechia
State/province [32] 0 0
Praha 2
Country [33] 0 0
Czechia
State/province [33] 0 0
Praha 5
Country [34] 0 0
France
State/province [34] 0 0
Avignon Cedex 9
Country [35] 0 0
France
State/province [35] 0 0
Bayonne
Country [36] 0 0
France
State/province [36] 0 0
Brest Cedex
Country [37] 0 0
France
State/province [37] 0 0
Creteil
Country [38] 0 0
France
State/province [38] 0 0
Le Mans
Country [39] 0 0
France
State/province [39] 0 0
Marseille Cedex 20
Country [40] 0 0
France
State/province [40] 0 0
Montpellier Cedex
Country [41] 0 0
France
State/province [41] 0 0
Nice
Country [42] 0 0
France
State/province [42] 0 0
Pau Cedex
Country [43] 0 0
France
State/province [43] 0 0
Saint Herblain
Country [44] 0 0
France
State/province [44] 0 0
Toulon
Country [45] 0 0
France
State/province [45] 0 0
Villejuif
Country [46] 0 0
Germany
State/province [46] 0 0
Berlin
Country [47] 0 0
Germany
State/province [47] 0 0
Dresden
Country [48] 0 0
Germany
State/province [48] 0 0
Gauting
Country [49] 0 0
Germany
State/province [49] 0 0
Halle
Country [50] 0 0
Germany
State/province [50] 0 0
Hamburg
Country [51] 0 0
Germany
State/province [51] 0 0
Hannover
Country [52] 0 0
Germany
State/province [52] 0 0
Homburg
Country [53] 0 0
Germany
State/province [53] 0 0
Köln
Country [54] 0 0
Germany
State/province [54] 0 0
Löwenstein
Country [55] 0 0
Germany
State/province [55] 0 0
Regensburg
Country [56] 0 0
Germany
State/province [56] 0 0
Trier
Country [57] 0 0
Germany
State/province [57] 0 0
Ulm
Country [58] 0 0
Germany
State/province [58] 0 0
Villingen-Schwenningen
Country [59] 0 0
Greece
State/province [59] 0 0
Athens
Country [60] 0 0
Greece
State/province [60] 0 0
Thessaloniki
Country [61] 0 0
Hong Kong
State/province [61] 0 0
Hong Kong
Country [62] 0 0
Hungary
State/province [62] 0 0
Miskolc
Country [63] 0 0
Hungary
State/province [63] 0 0
Törökbálint
Country [64] 0 0
Hungary
State/province [64] 0 0
Zalaegerszeg
Country [65] 0 0
Israel
State/province [65] 0 0
Tel Hashomer
Country [66] 0 0
Italy
State/province [66] 0 0
Aviano
Country [67] 0 0
Italy
State/province [67] 0 0
Candiolo
Country [68] 0 0
Italy
State/province [68] 0 0
Catania
Country [69] 0 0
Italy
State/province [69] 0 0
Cremona
Country [70] 0 0
Italy
State/province [70] 0 0
Genova
Country [71] 0 0
Italy
State/province [71] 0 0
Lucca
Country [72] 0 0
Italy
State/province [72] 0 0
Milano
Country [73] 0 0
Italy
State/province [73] 0 0
Monza
Country [74] 0 0
Italy
State/province [74] 0 0
Napoli
Country [75] 0 0
Italy
State/province [75] 0 0
Orbassano
Country [76] 0 0
Italy
State/province [76] 0 0
Parma
Country [77] 0 0
Italy
State/province [77] 0 0
Pisa
Country [78] 0 0
Italy
State/province [78] 0 0
Rimini
Country [79] 0 0
Italy
State/province [79] 0 0
Terni
Country [80] 0 0
Japan
State/province [80] 0 0
Fukuoka-shi
Country [81] 0 0
Japan
State/province [81] 0 0
Habikino-shi
Country [82] 0 0
Japan
State/province [82] 0 0
Hidaka-shi
Country [83] 0 0
Japan
State/province [83] 0 0
Hirakata-shi
Country [84] 0 0
Japan
State/province [84] 0 0
Hirosaki-shi
Country [85] 0 0
Japan
State/province [85] 0 0
Hiroshima-shi
Country [86] 0 0
Japan
State/province [86] 0 0
Kanazawa
Country [87] 0 0
Japan
State/province [87] 0 0
Kobe-shi
Country [88] 0 0
Japan
State/province [88] 0 0
Kurume-shi
Country [89] 0 0
Japan
State/province [89] 0 0
Matsuyama-shi
Country [90] 0 0
Japan
State/province [90] 0 0
Nagoya-shi
Country [91] 0 0
Japan
State/province [91] 0 0
Natori-shi
Country [92] 0 0
Japan
State/province [92] 0 0
Okayama-shi
Country [93] 0 0
Japan
State/province [93] 0 0
Osaka-shi
Country [94] 0 0
Japan
State/province [94] 0 0
Osakasayama
Country [95] 0 0
Japan
State/province [95] 0 0
Sakai-shi
Country [96] 0 0
Japan
State/province [96] 0 0
Sapporo-shi
Country [97] 0 0
Japan
State/province [97] 0 0
Sendai-shi
Country [98] 0 0
Japan
State/province [98] 0 0
Shinjuku-ku
Country [99] 0 0
Japan
State/province [99] 0 0
Sunto-gun
Country [100] 0 0
Japan
State/province [100] 0 0
Takatsuki-shi
Country [101] 0 0
Japan
State/province [101] 0 0
Wakayama-shi
Country [102] 0 0
Japan
State/province [102] 0 0
Yokohama-shi
Country [103] 0 0
Korea, Republic of
State/province [103] 0 0
Busan
Country [104] 0 0
Korea, Republic of
State/province [104] 0 0
Cheongju-si
Country [105] 0 0
Korea, Republic of
State/province [105] 0 0
Incheon
Country [106] 0 0
Korea, Republic of
State/province [106] 0 0
Jeonnam
Country [107] 0 0
Korea, Republic of
State/province [107] 0 0
Seongnam-si
Country [108] 0 0
Korea, Republic of
State/province [108] 0 0
Seoul
Country [109] 0 0
Netherlands
State/province [109] 0 0
Amsterdam
Country [110] 0 0
Poland
State/province [110] 0 0
Lublin
Country [111] 0 0
Poland
State/province [111] 0 0
Poznan
Country [112] 0 0
Poland
State/province [112] 0 0
Warszawa
Country [113] 0 0
Romania
State/province [113] 0 0
Alba Iulia
Country [114] 0 0
Romania
State/province [114] 0 0
Baia Mare
Country [115] 0 0
Romania
State/province [115] 0 0
Cluj Napoca
Country [116] 0 0
Romania
State/province [116] 0 0
Cluj-Napoca
Country [117] 0 0
Romania
State/province [117] 0 0
Onesti
Country [118] 0 0
Romania
State/province [118] 0 0
Oradea
Country [119] 0 0
Romania
State/province [119] 0 0
Timisoara
Country [120] 0 0
Russian Federation
State/province [120] 0 0
Arkhangelsk
Country [121] 0 0
Russian Federation
State/province [121] 0 0
Omsk
Country [122] 0 0
Russian Federation
State/province [122] 0 0
Saint Petersburg
Country [123] 0 0
Russian Federation
State/province [123] 0 0
St. Petersburg
Country [124] 0 0
Serbia
State/province [124] 0 0
Belgrade
Country [125] 0 0
Serbia
State/province [125] 0 0
Belgrad
Country [126] 0 0
Serbia
State/province [126] 0 0
Gornji Matejevac
Country [127] 0 0
Serbia
State/province [127] 0 0
Kragujevac
Country [128] 0 0
Serbia
State/province [128] 0 0
Sremska Kamenica
Country [129] 0 0
Singapore
State/province [129] 0 0
Singapore
Country [130] 0 0
Spain
State/province [130] 0 0
A Coruña
Country [131] 0 0
Spain
State/province [131] 0 0
Alicante
Country [132] 0 0
Spain
State/province [132] 0 0
Barcelona
Country [133] 0 0
Spain
State/province [133] 0 0
Girona
Country [134] 0 0
Spain
State/province [134] 0 0
Jaén
Country [135] 0 0
Spain
State/province [135] 0 0
Lleida
Country [136] 0 0
Spain
State/province [136] 0 0
Madrid
Country [137] 0 0
Spain
State/province [137] 0 0
San Sebastian
Country [138] 0 0
Spain
State/province [138] 0 0
Sevilla
Country [139] 0 0
Spain
State/province [139] 0 0
Valencia
Country [140] 0 0
Taiwan
State/province [140] 0 0
Taichung
Country [141] 0 0
Taiwan
State/province [141] 0 0
Tainan
Country [142] 0 0
Taiwan
State/province [142] 0 0
Taipei City
Country [143] 0 0
Taiwan
State/province [143] 0 0
Taipei
Country [144] 0 0
Thailand
State/province [144] 0 0
Bangkok
Country [145] 0 0
Thailand
State/province [145] 0 0
Muang
Country [146] 0 0
Thailand
State/province [146] 0 0
Phitsanulok
Country [147] 0 0
Thailand
State/province [147] 0 0
Songkla
Country [148] 0 0
United Kingdom
State/province [148] 0 0
Birmingham
Country [149] 0 0
United Kingdom
State/province [149] 0 0
London
Country [150] 0 0
United Kingdom
State/province [150] 0 0
Southampton
Country [151] 0 0
United Kingdom
State/province [151] 0 0
Stevenage
Country [152] 0 0
United Kingdom
State/province [152] 0 0
Truro
Country [153] 0 0
United Kingdom
State/province [153] 0 0
Wolverhampton

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AstraZeneca
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
This study is a Phase III, randomised, open label, multi-centre study assessing the efficacy and safety of MEDI4736 (durvalumab) versus Standard of Care in NSCLC patients with PD-L1 positive tumours and the combination of MEDI4736 (durvalumab) plus tremelimumab (MEDI4736+treme) versus Standard of Care in NSCLC patients with PD-L1-negative tumours in the treatment of male and female patients with locally advanced or metastatic NSCLC (Stage IIIB-IV), who have received at least 2 prior systemic treatment regimens including 1 platinum-based chemotherapy regimen for NSCLC. Patients with known EGFR (Epidermal growth factor receptor) tyrosine kinase (TK) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements are not eligible for the study (prospective testing is not planned within this study). The Standard of Care options are: an EGFR tyrosine kinase inhibitor (erlotinib \[TARCEVA®\]), gemcitabine or vinorelbine (NAVELBINE®)
Trial website
https://clinicaltrials.gov/study/NCT02352948
Trial related presentations / publications
Martin ML, Correll J, Walding A, Ryden A. How patients being treated for non-small cell lung cancer value treatment benefit despite side effects. Qual Life Res. 2022 Jan;31(1):135-146. doi: 10.1007/s11136-021-02882-6. Epub 2021 May 31.
Planchard D, Reinmuth N, Orlov S, Fischer JR, Sugawara S, Mandziuk S, Marquez-Medina D, Novello S, Takeda Y, Soo R, Park K, McCleod M, Geater SL, Powell M, May R, Scheuring U, Stockman P, Kowalski D. ARCTIC: durvalumab with or without tremelimumab as third-line or later treatment of metastatic non-small-cell lung cancer. Ann Oncol. 2020 May;31(5):609-618. doi: 10.1016/j.annonc.2020.02.006. Epub 2020 Feb 20.
Public notes

Contacts
Principal investigator
Name 0 0
Paul Stockman, MBChB, PhD
Address 0 0
AstraZeneca
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT02352948